cyrilzakka/clinical-trials huggingface dataset:
Incidence of Ocular Antibodies in Patients With Sturge - Weber Syndrome (SWS)

Sturge-Weber Syndrome (SWS) is a neurological disorder characterized at birth by seizures and a large port-wine stain birthmark on the forehead and upper eyelid of one side of the face. SWS is also accompanied by an increased pressure within the eye (glaucoma) which can develop very early in life.

Glaucoma represents a group of ocular disorders that are characterized by the loss of retinal ganglion cells and their axons, damage to the optic nerve, and gradual loss of visual field. Recently, several studies provided evidence that there is a potential role of the immune system in the pathogenesis of glaucoma.

These findings suggest that there might be changes in systemic humoral immunity possibly underlying the optic neuropathy in at least some glaucoma patients.

The ocular antibody profile in patients with SWS is unknown.The researchers want to study on blood and tear drop samples from patients with SWS to determine the incidence of ocular antibodies in patients with this syndrome.

Eligibility Criteria:
Inclusion Criteria:

* Male and female volunteers with SWS of all ages

Exclusion Criteria:

* Volunteers without SWS
Efficacy Long-term Dietary Nitrate Consumption to Plasma Nitrite Conversion

The objective of this study was to determine the chronic effects of beetroot juice supplementation on the acute (90-minute post nitrate consumption) efficacy of converting dietary nitrate to plasma nitrate and plasma nitrite in healthy middle-to-older aged adults. the investigators were also interested in determining the effect of this intervention on fasting levels of plasma nitrate and nitrite over time. Furthermore, the number of participants classified as "non-responders" was determined based on increases in plasma nitrite achieved using tolerable volumes of beetroot juice by other studies.


Eligibility Criteria:
Inclusion Criteria:

* Middle and Older (40-80 year-old) men and women
* Body mass index between 18.5 - 30.0 kg/m2
* Able to provide own transportation to study testing visits
* Able to consume study beverages
* Able to speak and read English

Exclusion Criteria:

* Tobacco user (smoke or chew), including e-cigarettes
* Known conditions of: diabetes mellitus (type 1 or 2), atrophic gastritis, hypo- or hyperthyroidism, gout, history of kidney stones, history of hypotension, cardiovascular disease, chronic obstructive pulmonary disease, inflammatory bowel diseases, impaired liver or kidney function
* Current or recent (last 3 months) treatment for cancer
* Current use of the following medications: Phosphodiesterase type 5 inhibitors, nitroglycerin or nitrate preparations, proton pump inhibitors, medication for hypothyroidism, antacid and heartburn medications
Risk Factors for Portosinusoidal Vascular Disease in Kidney Transplant Recipients:

To look for the factors of exposure present prior to the onset of Porto-Sinusoidal Vascular Disease (PSVD) and which can lead to the occurrence of PSVD after renal transplantation, and therefore to consider the identification of risk factors, in order to prevent or detect early signs of portal hypertention in predisposed patients and improve their prognosis.

Porto-Sinusoidal Vascular Disease (PSVD) is a heterogeneous clinico-pathological entity characterized by alterations in small liver vessels. The most common is known as "nodular regenerative hyperplasia (NRH)". Patients with PSVD especially NRH can developed portal hypertension. An acute portal thrombosis occurs in 1/3 of patients at five years. In case of portal hypertension, 10 years survival decreases down to 56 to 82%. De novo NRH has been described after liver transplantation (1 to 1.4% in adults, 8.2% in kids), and also in small series of kidney, cardiac and bone marrow transplantation. Prevalence is estimated to be 0.5% after kidney transplantation.

Several risks factors have been related to PSVD (infections, Immune-mediated disorders, haematological diseases, prothrombotic disorders, drugs such as azathioprine, genetic diseases). In transplantation, mechanical vascular factors, drugs, virus, immunogenetic and immunologic factors have been suggested, but none of them are well established.

The study aims to determined risk factors which can lead to PSVD in kidney transplant recipients, in order to prevent or to early detect portal hypertension and improve the prognosis of these patients. A case-control multicentric retrospective study will be done to compare adult kidney transplant recipients with PSVD with or without portal hypertension, to adult kidney transplant recipients without evidence for PSVD (matched according to the date of kidney transplantation of the case ± 2 years), and to non-transplanted adults with PSVD. Kidney transplant cases and controls will be recruited from French hepatogastroenterology and nephrology units. PSVD non transplanted controls will be recruited from the Beaujon Hospital database dedicated to liver vascular diseases.

Eligibility Criteria:
Inclusion Criteria:

* PSVD (between january 2000 and december 2021) after kidney transplantation or
* Kidney transplantation without PSVD or
* PSVD without kidney transplantation

Exclusion Criteria:

* liver cirrhosis
* transplanted from an other organ
* thrombocytopenia and/or abnormal liver tests and/or hepatic dysmorphism and/or portal hypertension signs
Effectiveness of Ultrasound Guided Adductor Canal Block on Chronic Pain in Knee Osteoarthritis

Adductor canal block has become popular as effective mean for pain relief following knee surgery.This block has not been checked in chronic pain patients.The purpose of this study is to assess the efficacy and safety of adductor canal block on chronic knee pain in patients with knee osteoarthritis.

Knee osteoarthritis is serious epidemiologic problem. Knee prosthesis is successful treatment for many of patients with advanced knee osteoarthritis but there are important numbers of patients, which are not appropriate candidates for such surgery treatment. For them ,any treatment which could relieve pain in their knee would have good impact on quality of life. Adductor canal block is successfully used for relieving postoperative pain after knee surgery. Official approval from ethics committee of Republic Slovenia was obtained for this study. After being informed about the study and potential risks, all patients giving written informed consent will undergo an orthopedic examination and those with confirmed diagnosis of knee osteoarthritis lasted more than 6 months will be included in the study. Prior to start they filled Knee injury and osteoarthritis outcome(KOOS) form and estimate maximal and minimal intensity of pain in the knee .They repeat self assessment of pain at the same manner using 11 point numeric rating score(NRS) 1 week and 1 month after blockade.Measurement of maximum voluntary isometric contraction of quadriceps muscle (MVIC) ,time up and go test(TUG) and 30s chair stand test are performed by physiotherapist before block of adductor canal on the ipsilateral leg ,1 hour,1 week and 1 month after block..Block of adductor canal is performed by the same and trained anesthesiologist at the proximal part of the leg using 14 ml of Levobupivacaine and 100 mcg Clonidine mixed in the same syringe.At the conclusion of study patients filled the Knee injury and osteoarthritis outcome(KOOS) form once again.

Eligibility Criteria:
Inclusion Criteria:

Outpatients Had pain in knee at least 6 months before the study Knee osteoarthritis chronic pain was diagnosed based on medical history, knee X- ray and orthopedic examination.

A sufficient level of education to understand study procedures and be able to communicate with site personnel

-

Exclusion Criteria:

* Any cardiovascular, hepatic, or renal conditions that would compromise participation, in the opinion of the investigator
* Severe neurologic conditions interfere with knee condition
* Narcotic dependent (opioid intake more than 3 months and more than 30 mg of daily oral morphine equivalents)
* Coexisting severe hematological disorder or with deranged coagulation parameters
* Psychiatric illnesses
* Allergy to any of the drugs used in the study
* Infection or malignancy at the site of block
* Any active systemic infection
Collection of Blood for Gene Expression Study in Individuals With Chronic Lung Diseases

This protocol is designed to gather a small amount of blood from patients seen in the New York Presbyterian Hospital-Weill Cornell Medical Center Pulmonary, Critical Care unit, and 5 West floor (Pulmonary Floor) for clinical care associated with chronic lung disease. This protocol will also survey medical records of patients with chronic lung disease, in order to study the clinical characteristics of these individuals. Investigators aim to understand the genetics of chronic lung diseases, and will use the serum and DNA from this blood to perform various genotyping studies such as such as genomic/gene expression studies of individuals with chronic lung diseases

This protocol is designed to gather a small amount of blood from patients seen in the New York Presbyterian Hospital-Weill Cornell Medical Center Pulmonary, Critical Care unit, and 5 West floor (Pulmonary Floor) for clinical care associated with chronic lung disease. This protocol will also survey medical records of patients with chronic lung disease, in order to study the clinical characteristics of these individuals. Investigators aim to understand the genetics of chronic lung diseases, and will use the serum and DNA from this blood to perform various genotyping studies such as such as genomic/gene expression studies of individuals with chronic lung diseases.

General admission criteria for this project will require at least one of the following: (1) symptoms consistent with pulmonary disease; (2) chest X-ray consistent with lung disease; (3) pulmonary function tests consistent with lung disease; (4) lung biopsy consistent with lung disease; (5) family history of lung disease; and (6) patients with diseases of organs with known association with lung disease.

The following studies will be conducted on blood specimens: genomic DNA will be extracted; promoter sequences for antioxidant-related genes will be obtained by PCR and sequenced. The goal is to find single nucleotide polymorphisms (SNP) to see if they correlate with lung disease. DNA samples and blood specimens will be coded. Samples could potentially be traced back to the patient. However, every effort will be made to keep the patient's identity confidential per HIPAA regulations.

The study does not aim to create a blood bank. Rather, the blood samples will be used for DNA extraction only. Serum will be stored for future studies, to look at levels of proteins.

Eligibility Criteria:
Inclusion Criteria:

* Must provide informed consent
* Males and females, age 18 years and older
* Lung disease proven by at least one of the following: (1) symptoms consistent with pulmonary disease; (2) chest X-rays consistent with lung disease; (3) pulmonary function tests consistent with lung disease; (4) lung biopsy consistent with lung disease; (5) family history of lung disease; and (6) diseases of organs with known association with lung disease

Exclusion Criteria:

* Drug and/or alcohol abuse within the past six months
* Females who are pregnant or nursing
Evaluating the Impact of an Integrative Oncology Training Program for Healthcare Providers

The goal of this study is to learn about the short- and long-term effects of two medical education approaches to teaching integrative oncology (IO) in a multi-disciplinary group of healthcare providers attending a national IO training. The main question it aims to answer is: Does active medical education approach focusing on IO-related skills is associated with better training outcomes compared to clerkship-based observation of IO clinics? Participants (trainees) will answer online survey questions about their knowledge, attitudes, and clinical proficiencies along the training process.

The study is conducted within a multi-centered, prospective, controlled and randomized format, using a mixed quantitative and qualitative methodology. Participants eligible for study inclusion are healthcare providers (HCPs, nurses, physicians, para-medical, or complementary medicine practitioners), age ≥ 18 years enrolling in a structured IO training program. Trainees are randomly allocated to either the Enhanced IO Training arm (Group A) or Standard IO Training arm of the study (Group B). Participants in both study arms undergo 110-hour online section of the IO training course, followed by 170-hour practical training.

Those in the Enhanced IO Training arm undergo practical training, based on the five-item competency curriculum adapted from the list of knowledge, skills, and ability-related competencies recommended by the Society for Integrative Oncology. The five-item competency-based curriculum include the following two clinical implementation competencies:

* Anxiety relief using a mind-body modality (e.g., breathing, relaxation, guided imagery)
* Improving pain with touch modalities (e.g., acupressure, acupuncture, reflexology), including use of acupressure points with established effectiveness in the reduction of cancer pain Participants in the Standard IO training group (Group B) will observe from the side during the IO practitioner-patient interaction.

The practical section of the training program will include two mentoring days, the first scheduled at the beginning of the 110-hour theory-based IO training, the second at the conclusion of this training. Participants in both study groups will be exposed during the two mentoring days to between 3-5 clinical IO therapeutic interactions with patients admitted to the oncology center.

Eligibility Criteria:
Inclusion Criteria:

* Healthcare providers (nurses, physicians, para-medical, or complementary medicine practitioners) who have applied to and been accepted for the integrative oncology training program

Exclusion Criteria:

* Healthcare providers who were not received a letter of support from the medical administrator stating commitment to allocate at least 5 hours weekly post-training to enable the trainee practicing integrative oncology care in the medical center.
Treatment of TK2 Deficiency with Thymidine and Deoxycytidine

Patients with confirmed mitochondrial DNA depletion syndrome 2 (thymidine kinase 2 \[TK2\] deficiency) have reduced levels of nucleotides (deoxythymidine monophosphate and deoxycytidine monophosphate) for mitochondrial DNA synthesis. This results in mitochondrial DNA depletion syndrome (i.e less number of functional mitochondrial DNA). Patients with confirmed TK2 deficiency will be treated with open label deoxythymidine (dThd) and deoxycytidine (dCyt), which are nucleotide precursors, with the expectation that the cells could make additional mitochondrial DNA. This in turn may help reduce the clinical symptoms.

Mitochondrial are responsible for the production of cellular energy. Mitochondria contain DNA which is the encoding system ( "recipe") for making the proteins that allow the mitochondria to function. Reduced amount of mitochondrial DNA, caused by genetic mutations in certain genes, Mitochondrial DNA Depletion Syndrome. This can result in symptoms; such as fatigue, weakness, and deficiencies in various body systems. TK2 deficiency is considered a mitochondrial depletion syndrome. Patients with TK2 deficiency have weakness and walking difficulty. They also have depleted levels of chemicals (phosphorylated deoxythymidine and deoxycytidine) used to make mitochondrial DNA. Based on previous studies with a similar compound, patients reported more energy and better motor skills.

Eligible patients include those with genetic mutations in the TK2 gene who are willing to attend several outpatient visits, and have motor skills testing, neurological exam by doctor, and blood samples.

Eligibility Criteria:
Inclusion Criteria:

* Genetically confirmed diagnosis of TK2 deficiency
* Deemed by principle investigator to be symptomatic with TK2 deficiency
* Single gene disease; absence of polygenic disease
* Hematocrit within normal range for age group
* Patient or patient's guardian able to consent and comply with protocol requirements
* Presence of caregiver to ensure study compliance (if needed)
* Abstention from use of all pill-form dietary supplements and non-prescribed medications (except as allowed by the investigator)
* Abstention from use of other investigational medications or other medications according to the study investigator

Exclusion Criteria:

* Clinical history of bleeding or abnormal prothrombin time (PT)/partial thromboplastin time (PTT)
* Hepatic insufficiency with liver function tests (LFTs) greater than two times normal
* Renal insufficiency requiring dialysis
* Any other concurrent inborn errors of metabolism
* Severe end-organ hypo-perfusion syndrome secondary to cardiac failure resulting in lactic acidosis
Low Fat Diet and Multiple Sclerosis

The purpose of this study is to evaluate if following a specific low fat diet will improve the brain damage as seen by Magnetic Resonance Imaging (MRI) and to decrease the progression of multiple sclerosis (MS) as evidenced by clinical evaluation and symptoms.

This research project has significance for its potential to develop a new therapeutic approach to MS. Current treatments in MS include disease modifying therapies such as human recombinant interferon beta, glatiramer acetate and natalizumab. However, these are only partially effective, cannot be taken orally, have side-effects and are very expensive. Developing treatment that can be combined with current disease modifying agent remains an important goal for improving the care of people with MS.

Eligibility Criteria:
Inclusion Criteria:

* Clinical diagnosis of the relapsing-remitting form of MS
* Age 18-70, inclusive
* MS duration of less than 15 years
* May or may not be on disease-modifying therapies for MS, but if on, must be on for more than 6 months of continuous therapy
* Should not have diabetes
* Able and willing to follow exercise instructions
* Able and willing to travel to California for 10-day training program (cost covered by study)
* Able and willing to travel to Portland, OR for 6 study visits over the 12 month study period (cost covered by study)

Exclusion Criteria:

* No clinically significant MS exacerbation within 30 days of screening visit
* No systemically administered corticosteroids within 30 days of study entry
* Patient not pregnant or breastfeeding
* Not taking fish oil/flax seed for at least 2 months prior to first visit
* No other significant health programs (e.g. active coronary heart disease, liver disease, pulmonary disease) that might increase risk of patient experiencing adverse events
Survey of Patients With Idiopathic Orbital Inflammation Syndrome

The purpose of this study is to characterise the clinical features, histopathology and the treatment outcomes of patients with idiopathic orbital inflammation syndrome.

Idiopathic orbital inflammatory syndrome (IOIS) is a heterogeneous group of disorders characterised by orbital inflammation without any identifiable local or systemic causes. It is a rare clinical entity and a diagnosis of exclusion. Lymphomas, thyroid eye diseases or systemic diseases can have similar presentation and so, a histopathological diagnosis is considered important. IOIS is a difficult condition to treat. Compilation of reported small series of patients with IOIS suggested that they require multiple systemic immunosuppressant drugs and radiotherapy. Recently, a large monocentric study including patients with biopsy proven IOIS showed that up to 40% of them can relapse. Their clinical and pathological features did not correlate with treatments outcomes. The investigators decide therefore to conduct a multicentric retro/ prospective study to determine clinical features, histopathology and treatment outcomes of French patients with IOIS.

Eligibility Criteria:
Inclusion Criteria:

* Patients with biopsy proven IOIS or presumed IOIS
* Patients with chronic IOS
* Patient with inaugural IOIS or being treated for IOIS

Exclusion Criteria:

* Patients who do not fulfill the inclusion criteria
* Patients with systemic disease-associated IOIS
* Incomplete follow-up of patients treated for IOIS
Safety and Tolerability of Acanya Gel in Combination With Atralin Gel for Acne Vulgaris

The purpose of this study is to evaluate whether Cerave lotion followed by Acanya Gel in the morning in combination with Cerave lotion followed by Atralin gel in the evening is safe and effective for the treatment of acne vulgaris.


Eligibility Criteria:
Inclusion Criteria:

* Males and females ≥ 12 years old.
* Subjects must be in good general health as confirmed by medical history and physical examination.
* Females of child-bearing potential must have a negative urine pregnancy test at the baseline visit and agree to be abstinent or use adequate birth control during the study (oral contraceptives, Norplant, Depo-Provera, or double barrier methods (e.g., condom and spermicide).
* Clear diagnosis of facial acne vulgaris for at least 6 months.
* Subject must have a static Physician's Global Assessment (PGA) of 2 (mild severity) or 3 (moderate severity).
* Disease must be stable or slowly worsening for more than one week prior to entering the study.
* Subjects or their guardians must be able to read, sign, and date the informed consent, and abide by study restrictions for its duration.

Exclusion Criteria:

* Females who are pregnant, attempting to conceive, or breastfeeding.
* Subjects with known hypersensitivity to any ingredients in the study drugs.
* Subjects with overt signs of skin atrophy, telangiectasias or other skin findings that would affect efficacy evaluation.
* Subjects with a current active skin malignancy or infection.
* Subjects requiring the use of medications known to alter the course of acne vulgaris during the study treatment.
* Subjects who have received systemic antibiotics within 2 weeks.
* Subjects using systemic corticosteroids or immunosuppressants within 28 days of entering the study.
* Subjects who have received any topical therapies for acne vulgaris within 7 days of entering the study.
* Subjects taking birth control pills used solely for acne control.
* Subjects who are currently participating in or, within the previous 28 days, have participated in another study for the treatment of acne vulgaris.
* Subjects with clinical conditions that may post a health risk to the subject by being involved in the study or detrimentally affect regular follow-up of the subject.
* Subjects who have Crohn's disease, colitis, or if subjects ever developed colitis or severe diarrhea with past antibiotic use.